MAD2L2 dimerization and TRIP13 control shieldin activity in DNA repair

DSpace/Manakin Repository

MAD2L2 dimerization and TRIP13 control shieldin activity in DNA repair
 
de Krijger, Inge; Föhr, Bastian; Pérez, Santiago Hernández; Vincendeau, Estelle; Serrat, Judit; Thouin, Alexander Marc; Susvirkar, Vivek; Lescale, Chloé; Paniagua, Inés; Hoekman, Liesbeth; Kaur, Simranjeet; Altelaar, Maarten; Deriano, Ludovic; Faesen, Alex C; Jacobs, Jacqueline J L
(2021) Nature Communications, volume 12, issue 1
(Article)
Abstract
MAD2L2 (REV7) plays an important role in DNA double-strand break repair. As a member of the shieldin complex, consisting of MAD2L2, SHLD1, SHLD2 and SHLD3, it controls DNA repair pathway choice by counteracting DNA end-resection. Here we investigated the requirements for shieldin complex assembly and activity. Besides a dimerization-surface, HORMA-domain ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
 
Keywords: General Chemistry, General Biochemistry,Genetics and Molecular Biology, General Physics and Astronomy
DOI: https://doi.org/10.1038/s41467-021-25724-y
ISSN: 2041-1723
Publisher: Nature Publishing Group
Note: Funding Information: We thank T. de Lange for the Trf2ts allele and Trf2flox/−;p53−/− MEFs, D. Durocher for BRCA1−/− RPE, R. Greenberg for U2OS-DSB reporter cells with inducible mCherry-LacI-Fok1 nuclease, G. Vader for HeLa cells expressing doxycycline-inducible GFP-tagged TRIP13EQ and TRIP13 expression constructs, B. de Wolf and G. Kops for TRIP13 KO HeLa, G. Legube for AID-DIvA U2OS cells, J. Stark for DR-GFP U2OS cells, C. Choudhary for GFP-RINN1 (SHLD3) and RINN2 (SHLD2) expression constructs, M. Barazas for pX330p-sgNT, B. van den Broek for customized macros for image analysis and R. Medema and B. Rowland labs for discussions. This work was supported by project grant 10999/2017-1 from the Dutch Cancer Society (KWF) to J.J.L.J., by the Institut Pasteur to L.D., by the Institut National Du Cancer (INCA_13852) to L.D., by the Ligue Nationale Contre le Cancer (Equipe labellisée 2019) to L.D. The Proteomics Facility of the Netherlands Cancer Institute was supported by the X-omics Initiative, partially funded by the Dutch Research Council (NWO)(project 184.034.019). E.V. received funding from Université de Paris, Sorbonne Paris Cité. A.C.F. is grateful for generous core funding by the Max Planck Society. Publisher Copyright: © 2021, The Author(s).
(Peer reviewed)
 
See more statistics about this item